,docId,isValid,passage,passage_id,e1,e2
0,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (PROTEIN1 and PROTEIN2) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0,TFIIIC102,TFIIIC63
1,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (PROTEIN1 and PROTEIN263) of human PROTEIN2 and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0,TFIIIC102,TFIIIC
2,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (PROTEIN2102 and PROTEIN1) of human PROTEIN2 and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0,TFIIIC63,TFIIIC
3,HPRD50.d1,True,"Identification of residues in the PROTEIN1 that contact the MCP-1 receptor, PROTEIN2",HPRD50.d1.s0,monocyte chemotactic protein-1,CCR2
4,HPRD50.d1,False,"The receptor binding site of PROTEIN1 also is significantly different from the binding sites of PROTEIN2 and IL-8, providing insight into the issue of receptor specificity",HPRD50.d1.s1,MCP-1,RANTES
5,HPRD50.d1,False,"The receptor binding site of PROTEIN1 also is significantly different from the binding sites of RANTES and PROTEIN2, providing insight into the issue of receptor specificity",HPRD50.d1.s1,MCP-1,IL-8
6,HPRD50.d1,False,"The receptor binding site of MCP-1 also is significantly different from the binding sites of PROTEIN1 and PROTEIN2, providing insight into the issue of receptor specificity",HPRD50.d1.s1,RANTES,IL-8
7,HPRD50.d1,True,It was previously shown that the N-terminus of PROTEIN1 is critical for binding PROTEIN2,HPRD50.d1.s2,CCR2,MCP-1
8,HPRD50.d1,True,"To identify the regions of PROTEIN1 that contact its receptor, PROTEIN2, we substituted all surface-exposed residues with alanine",HPRD50.d1.s3,MCP-1,CCR2
9,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the PROTEIN1 subunit or the PROTEIN2a and FSH beta monomer,HPRD50.d2.s0,CG beta,CG beta alpha
10,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the PROTEIN1 subunit or the PROTEIN1 alpha andPROTEIN2a monomer,HPRD50.d2.s0,CG beta,FSH beta
11,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the PROTEIN1 and PROTEIN2 monomer,HPRD50.d2.s0,CG beta alpha,FSH beta
12,HPRD50.d2,False,The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/PROTEIN1 subunit since CG single chain interacts with the monomeric PROTEIN2 subunit and exhibits FSH activity,HPRD50.d2.s1,CG beta,FSH beta
13,HPRD50.d2,False,"This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the PROTEIN1 or PROTEIN2 subunits are different",HPRD50.d2.s2,LH beta,FSH beta
14,HPRD50.d2,False,"Previously, we showed that the PROTEIN1 or PROTEIN2 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, PROTEIN1 alpha and F beta alpha, respectively",HPRD50.d2.s3,CG beta,FSH beta
15,HPRD50.d2,False,"Previously, we showed that the PROTEIN1 or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, PROTEIN2a and F beta alpha, respectively",HPRD50.d2.s3,CG beta,CG beta alpha
16,HPRD50.d2,False,"Previously, we showed that the CG beta or PROTEIN1 subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, PROTEIN2 and F beta alpha, respectively",HPRD50.d2.s3,FSH beta,CG beta alpha
17,HPRD50.d3,True,"PROTEIN1 activates PROTEIN2, which inhibits apoptosis in human prostate cancer cell lines",HPRD50.d3.s0,Interleukin-6,phosphatidylinositol-3 kinase
18,HPRD50.d3,False,RESULTS: Tyrosine phosphorylation of p85 is upregulated by PROTEIN1 in both LNCaP and PROTEIN2,HPRD50.d3.s1,IL-6,PC-3
19,HPRD50.d3,True,"PROTEIN1 promotes coprecipitation of p85 with PROTEIN2, the signal-transducing component of the PROTEIN1 receptor",HPRD50.d3.s2,IL-6,gp130
20,HPRD50.d3,False,"PROTEIN1 promotes coprecipitation of p85 with gp130, the signal-transducing component of the PROTEIN2ptor",HPRD50.d3.s2,IL-6,IL-6 receptor
21,HPRD50.d3,False,"IL-6 promotes coprecipitation of p85 with PROTEIN1, the signal-transducing component of the PROTEIN2",HPRD50.d3.s2,gp130,IL-6 receptor
22,HPRD50.d4,False,"In solution, FGFR4ed formed complexes with PROTEIN1 and PROTEIN2, both in the presence and absence of heparin",HPRD50.d4.s0,acidic FGF (FGF-1),basic FGF (FGF-2)
23,HPRD50.d4,True,Immobilized PROTEIN1 also bound PROTEIN2 besides FGF-1 and FGF-2,HPRD50.d4.s1,FGFR4,FGF-8
24,HPRD50.d4,True,Immobilized PROTEIN1 also bound FGF-8 besides PROTEIN2 and FGF-2,HPRD50.d4.s1,FGFR4,FGF-1
25,HPRD50.d4,True,Immobilized PROTEIN1 also bound FGF-8 besides FGF-1 and PROTEIN2,HPRD50.d4.s1,FGFR4,FGF-2
26,HPRD50.d4,False,Immobilized FGFR4 also bound PROTEIN1 besides PROTEIN2 and FGF-2,HPRD50.d4.s1,FGF-8,FGF-1
27,HPRD50.d4,False,Immobilized FGFR4 also bound PROTEIN1 besides FGF-1 and PROTEIN2,HPRD50.d4.s1,FGF-8,FGF-2
28,HPRD50.d4,False,Immobilized FGFR4 also bound FGF-8 besides PROTEIN1 and PROTEIN2,HPRD50.d4.s1,FGF-1,FGF-2
29,HPRD50.d5,True,PROTEIN1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with PROTEIN2,HPRD50.d5.s0,Cytohesin-1,LFA-1
30,HPRD50.d5,True,"Here we provide evidence of how PROTEIN1, an integrin-binding protein and guanine-nucleotide exchange factor (GEF) for PROTEIN2 GTPases, regulates cell adhesion",HPRD50.d5.s1,cytohesin-1,ARF
31,HPRD50.d5,True,"Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of PROTEIN1 depends on its interaction with PROTEIN2, unless the integrin is activated by exogenous divalent cations",HPRD50.d5.s2,LFA-1,cytohesin-1
32,HPRD50.d5,True,"Secondly, PROTEIN1 induces expression of an extracellular activation epitope of PROTEIN2, and the exchange factor function is not essential for this activity",HPRD50.d5.s3,cytohesin-1,LFA-1
33,HPRD50.d5,True,"In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a PROTEIN1 mutant, which fails to catalyze PROTEIN2 GDP-GTP exchange in vitro",HPRD50.d5.s4,cytohesin-1,ARF
34,HPRD50.d5,True,"Thus, PROTEIN1 is involved in the activation of PROTEIN2, most probably through direct interaction with the integrin, and induces cell spreading by its ARF-GEF activity",HPRD50.d5.s5,cytohesin-1,LFA-1
35,HPRD50.d7,True,Suppression of rat thromboxane synthase gene transcription by PROTEIN1 in macrophages via an interaction with PROTEIN2,HPRD50.d7.s0,peroxisome proliferator-activated receptor gamma,NRF2
36,HPRD50.d7,False,"Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 (PROTEIN1)/PROTEIN2 site (-98/-88), which was indicated to be the major promoter of the TXS gene",HPRD50.d7.s1,NF-E2,AP-1
37,HPRD50.d7,False,"By electrophoretic mobility shift assay using the PROTEIN1/PROTEIN2 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (PROTEIN1-related factor 2)",HPRD50.d7.s2,NF-E2,AP-1
38,HPRD50.d7,False,"By electrophoretic mobility shift assay using the PROTEIN1/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor PROTEIN2 (PROTEIN1-related factor 2)",HPRD50.d7.s2,NF-E2,NRF2
39,HPRD50.d7,False,"By electrophoretic mobility shift assay using the PROTEIN1/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (PROTEIN2r 2)",HPRD50.d7.s2,NF-E2,NF-E2-related factor 2
40,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/PROTEIN1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor PROTEIN2 (NF-E2-related factor 2)",HPRD50.d7.s2,AP-1,NRF2
41,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/PROTEIN1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (PROTEIN2)",HPRD50.d7.s2,AP-1,NF-E2-related factor 2
42,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor PROTEIN1 (PROTEIN2)",HPRD50.d7.s2,NRF2,NF-E2-related factor 2
43,HPRD50.d7,False,"Finally, a direct interaction between PPARgamma and PROTEIN1 was confirmed by PROTEIN2 pull-down assay",HPRD50.d7.s3,NRF2,glutathione S-transferase
44,HPRD50.d8,False,"By constructing deletion mutants, we identified that amino acid residues 229-309 of Akt were involved in the binding to PROTEIN1 and amino acid residues 327-340 of PROTEIN2eta were involved in the binding to Akt",HPRD50.d8.s0,Hsp90,Hsp90beta
45,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human PROTEIN1 protein as an atypical PROTEIN2 (named PROTEIN2 XIII)",HPRD50.d9.s0,KIAA1427,Syt
46,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human PROTEIN1 protein as an atypical Syt (named PROTEIN2)",HPRD50.d9.s0,KIAA1427,Syt XIII
47,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical PROTEIN2 (named PROTEIN2 XIII)",HPRD50.d9.s0,Syt,Syt XIII
48,HPRD50.d9,False,"Subcellular fractionation and antibody-uptake experiments indicate that PROTEIN1 is indeed a type-I membrane protein, but, unlike other PROTEIN2 isoforms, lacks an N-terminal extracellular domain",HPRD50.d9.s1,Syt XIII,Syt
49,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of PROTEIN1 and the Src homology 3 domain of PROTEIN2 activates phosphatidylinositol 3-kinase in C2C12 cells,HPRD50.d11.s0,ADAM 12,p85alpha
50,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of PROTEIN1 and the Src homology 3 domain of p85alpha activates PROTEIN2 in C2C12 cells,HPRD50.d11.s0,ADAM 12,phosphatidylinositol 3-kinase
51,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of PROTEIN1 activates PROTEIN2 in C2C12 cells,HPRD50.d11.s0,p85alpha,phosphatidylinositol 3-kinase
52,HPRD50.d11,True,"This suggests that transmembrane PROTEIN1, by providing docking sites for the Src homology 3 domain of PROTEIN2, activates PI 3-kinase by mediating its recruitment to the membrane",HPRD50.d11.s1,ADAM 12,p85alpha
53,HPRD50.d12,True,PROTEIN1 binds to the C-terminal SH2 domain of PROTEIN2 and inhibits its enzymatic activity,HPRD50.d12.s0,AP180,phospholipase C-gamma1
54,HPRD50.d12,True,"In this report, we demonstrate the stable association of PROTEIN1 with PROTEIN2 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PROTEIN1, but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1,PLCgamma1,AP180
55,HPRD50.d12,True,"In this report, we demonstrate the stable association of PROTEIN2 with PROTEIN1 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PROTEIN2, but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1,AP180,PLCgamma1
56,HPRD50.d12,False,"In this report, we demonstrate the stable association of PROTEIN1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PROTEIN2 but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1,PLCgamma1,PLCgamma1
57,HPRD50.d13,True,Here we demonstrate colocalization and direct interaction between PROTEIN1 and PROTEIN2,HPRD50.d13.s0,CLIP-170,LIS1
58,HPRD50.d13,True,"Overexpression of PROTEIN1 results in a zinc finger-dependent localization of a PROTEIN2 isoform and dynactin to MT bundles, raising the possibility that PROTEIN1 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,CLIP-170,phospho-LIS1
59,HPRD50.d13,False,"Overexpression of PROTEIN2 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that PROTEIN2 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,CLIP-170,CLIP-170
60,HPRD50.d13,False,"Overexpression of PROTEIN1 results in a zinc finger-dependent localization of a phospho-PROTEIN2 isoform and dynactin to MT bundles, raising the possibility that PROTEIN1 and PROTEIN2 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,CLIP-170,LIS1
61,HPRD50.d13,False,"Overexpression of PROTEIN2 results in a zinc finger-dependent localization of a PROTEIN1 isoform and dynactin to MT bundles, raising the possibility that PROTEIN2 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,phospho-LIS1,CLIP-170
62,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a PROTEIN1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and PROTEIN2 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,phospho-LIS1,LIS1
63,HPRD50.d13,False,"Overexpression of PROTEIN1 results in a zinc finger-dependent localization of a phospho-PROTEIN2 isoform and dynactin to MT bundles, raising the possibility that PROTEIN1 and PROTEIN2 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,CLIP-170,LIS1
64,HPRD50.d13,True,"This work suggests that PROTEIN1 is a regulated adapter between PROTEIN2 and cytoplasmic dynein at sites involved in cargo-MT loading, and/or in the control of MT dynamics",HPRD50.d13.s2,LIS1,CLIP-170
65,HPRD50.d14,False,PROTEIN1 and PROTEIN2: multifunctional endocytic receptors,HPRD50.d14.s0,Megalin,cubilin
66,HPRD50.d14,True,PROTEIN1 and PROTEIN2 are two structurally different endocytic receptors that interact to serve such functions,HPRD50.d14.s1,Megalin,cubilin
67,HPRD50.d16,True,PROTEIN1 and GADD45g are PROTEIN2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0,GADD45b,cdc2
68,HPRD50.d16,True,GADD45b and PROTEIN1 are PROTEIN2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0,GADD45g,cdc2
69,HPRD50.d16,False,PROTEIN1 and PROTEIN2 are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0,GADD45b,GADD45g
70,HPRD50.d16,False,"PROTEIN1 (PROTEIN2), PROTEIN2b (MyD118), and PROTEIN2g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,Gadd45
71,HPRD50.d16,False,"PROTEIN1 (Gadd45), PROTEIN2 (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,Gadd45b
72,HPRD50.d16,False,"PROTEIN1 (Gadd45), Gadd45b (PROTEIN2), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,MyD118
73,HPRD50.d16,False,"PROTEIN1 (Gadd45), Gadd45b (MyD118), and PROTEIN2 (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,Gadd45g
74,HPRD50.d16,False,"PROTEIN1 (Gadd45), Gadd45b (MyD118), and Gadd45g (PROTEIN2) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,CR6
75,HPRD50.d16,False,"PROTEIN1a (PROTEIN1)PROTEIN2IN1b (MyD118), and PROTEIN1g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45,Gadd45b
76,HPRD50.d16,False,"PROTEIN1a (PROTEIN1), PROTEINPROTEIN2D118), and PROTEIN1g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45,MyD118
77,HPRD50.d16,False,"PROTEIN1a (PROTEIN1), PROTEIN1b (MyD118), PROTEIN2TEIN1g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45,Gadd45g
78,HPRD50.d16,False,"PROTEPROTEIN2a (PROTEPROTEIN2), PROTEPROTEIN2b (MyD118), and PROTEPROTEIN2g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45,CR6
79,HPRD50.d16,False,"Gadd45a (Gadd45), PROTEIN1 (PROTEIN2), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45b,MyD118
80,HPRD50.d16,False,"Gadd45a (Gadd45), PROTEIN1 (MyD118), and PROTEIN2 (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45b,Gadd45g
81,HPRD50.d16,False,"Gadd45a (Gadd45), PROTEIN1 (MyD118), and Gadd45g (PROTEIN2) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45b,CR6
82,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (PROTEIN1), and PROTEIN2 (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,MyD118,Gadd45g
83,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (PROTEIN1), and Gadd45g (PROTEIN2) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,MyD118,CR6
84,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and PROTEIN1 (PROTEIN2) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45g,CR6
85,HPRD50.d16,True,Recent evidence has implicated PROTEIN1 in inhibition of PROTEIN2/cyclinB1 kinase and in G2/M cell cycle arrest,HPRD50.d16.s2,Gadd45a,cdc2
86,HPRD50.d16,True,"Yet, whether PROTEIN1 and/or Gadd45g function as inhibitors of PROTEIN2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3,Gadd45b,cdc2
87,HPRD50.d16,True,"Yet, whether Gadd45b and/or PROTEIN1 function as inhibitors of PROTEIN2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3,Gadd45g,cdc2
88,HPRD50.d16,False,"Yet, whether PROTEIN1 and/or PROTEIN2 function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3,Gadd45b,Gadd45g
89,HPRD50.d16,True,"In this work, we show that PROTEIN1 and Gadd45g specifically interact with the PROTEIN2/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4,Gadd45b,Cdk1
90,HPRD50.d16,True,"In this work, we show that Gadd45b and PROTEIN1 specifically interact with the PROTEIN2/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4,Gadd45g,Cdk1
91,HPRD50.d16,False,"In this work, we show that PROTEIN1 and PROTEIN2 specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4,Gadd45b,Gadd45g
92,HPRD50.d16,True,"Data also has been obtained that PROTEIN1 and Gadd45g, as well as GADD45a, interact with both PROTEIN2 and cyclinB1, resulting in inhibition of the kinase activity of the PROTEIN2/cyclinB1 complex",HPRD50.d16.s5,Gadd45b,Cdk1
93,HPRD50.d16,True,"Data also has been obtained that PROTEIN1 and Gadd45g, as well as GADD45a, interact with both PROTEIN2 and cyclinB1, resulting in inhibition of the kinase activity of the PROTEIN2/cyclinB1 complex",HPRD50.d16.s5,Gadd45b,Cdk1
94,HPRD50.d16,True,"Data also has been obtained that Gadd45b and PROTEIN1, as well as GADD45a, interact with both PROTEIN2 and cyclinB1, resulting in inhibition of the kinase activity of the PROTEIN2/cyclinB1 complex",HPRD50.d16.s5,Gadd45g,Cdk1
95,HPRD50.d16,True,"Data also has been obtained that Gadd45b and PROTEIN1, as well as GADD45a, interact with both PROTEIN2 and cyclinB1, resulting in inhibition of the kinase activity of the PROTEIN2/cyclinB1 complex",HPRD50.d16.s5,Gadd45g,Cdk1
96,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as PROTEIN1, interact with both PROTEIN2 and cyclinB1, resulting in inhibition of the kinase activity of the PROTEIN2/cyclinB1 complex",HPRD50.d16.s5,GADD45a,Cdk1
97,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as PROTEIN1, interact with both PROTEIN2 and cyclinB1, resulting in inhibition of the kinase activity of the PROTEIN2/cyclinB1 complex",HPRD50.d16.s5,GADD45a,Cdk1
98,HPRD50.d16,False,"Data also has been obtained that PROTEIN1 and PROTEIN2, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45b,Gadd45g
99,HPRD50.d16,False,"Data also has been obtained that PROTEIN1 and Gadd45g, as well as PROTEIN2, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45b,GADD45a
100,HPRD50.d16,False,"Data also has been obtained that Gadd45b and PROTEIN1, as well as PROTEIN2, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45g,GADD45a
101,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both PROTEIN2EIN1 and cyclinB1, resulting in inhibition of the kinase activity of the PROTEIN2EIN1/cyclinB1 complex",HPRD50.d16.s5,Cdk1,Cdk1
102,HPRD50.d16,True,"Inhibition of PROTEIN1/cyclinB1 kinase activity by PROTEIN2 and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Cdk1,Gadd45b
103,HPRD50.d16,True,"Inhibition of PROTEIN1/cyclinB1 kinase activity by Gadd45b and PROTEIN2 was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Cdk1,Gadd45a
104,HPRD50.d16,False,"Inhibition of PROTEIN1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas PROTEIN2 did not disrupt the complex",HPRD50.d16.s6,Cdk1,Gadd45g
105,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by PROTEIN1 and PROTEIN2 was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Gadd45b,Gadd45a
106,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by PROTEIN1 and Gadd45a was found to involve disruption of the complex, whereas PROTEIN2 did not disrupt the complex",HPRD50.d16.s6,Gadd45b,Gadd45g
107,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and PROTEIN1 was found to involve disruption of the complex, whereas PROTEIN2 did not disrupt the complex",HPRD50.d16.s6,Gadd45a,Gadd45g
108,HPRD50.d18,True,The transmembrane PROTEIN1 DEP1 interacts with PROTEIN2,HPRD50.d18.s0,receptor protein tyrosine phosphatase,p120(ctn)
109,HPRD50.d18,True,The transmembrane receptor protein tyrosine phosphatase PROTEIN1 interacts with PROTEIN2,HPRD50.d18.s0,DEP1,p120(ctn)
110,HPRD50.d18,False,The transmembrane PROTEIN1 PROTEIN2 interacts with p120(ctn),HPRD50.d18.s0,receptor protein tyrosine phosphatase,DEP1
111,HPRD50.d18,False,"The PROTEIN1 PROTEIN2, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1,receptor-like protein tyrosine phosphatase,DEP1
112,HPRD50.d18,False,"The PROTEIN1 DEP1, also known as PROTEIN2, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1,receptor-like protein tyrosine phosphatase,CD148
113,HPRD50.d18,False,"The receptor-like protein tyrosine phosphatase PROTEIN1, also known as PROTEIN2, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1,DEP1,CD148
114,HPRD50.d18,True,PROTEIN1 also interacted with other members of the catenin gene family including PROTEIN2 and gamma-catenin,HPRD50.d18.s2,DEP1,beta-catenin
115,HPRD50.d18,False,"The interaction with PROTEIN1 is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and PROTEIN2 expression",HPRD50.d18.s3,p120(ctn),E-cadherin
116,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PROTEIN1, PROTEIN2, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific",HPRD50.d18.s4,PTP-PEST,CD45
117,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PROTEIN1, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of PROTEIN2 with these proteins is specific",HPRD50.d18.s4,PTP-PEST,DEP1
118,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PTP-PEST, PROTEIN1, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of PROTEIN2 with these proteins is specific",HPRD50.d18.s4,CD45,DEP1
119,HPRD50.d19,True,PROTEIN1/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (PROTEIN2) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,p300,MEF2A
120,HPRD50.d19,True,p300/PROTEIN1 ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (PROTEIN2) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,cAMP-response-element-binding-protein,MEF2A
121,HPRD50.d19,True,p300/cAMP-response-element-binding-protein ('PROTEIN1')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (PROTEIN2) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,CREB,MEF2A
122,HPRD50.d19,False,PROTEIN1/PROTEIN2 ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,p300,cAMP-response-element-binding-protein
123,HPRD50.d19,False,PROTEIN1/cAMP-response-element-binding-protein ('PROTEIN2')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,p300,CREB
124,HPRD50.d19,False,p300/PROTEIN1 ('PROTEIN2')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,cAMP-response-element-binding-protein,CREB
125,HPRD50.d19,False,PROTEIN1/PROTEIN2 ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1,p300,cAMP-response-element-binding-protein
126,HPRD50.d19,False,PROTEIN1/cAMP-response-element-binding-protein ('PROTEIN2')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1,p300,CREB
127,HPRD50.d19,False,p300/PROTEIN1 ('PROTEIN2')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1,cAMP-response-element-binding-protein,CREB
128,HPRD50.d19,True,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and PROTEIN2, and our in vivo studies demonstrated that TR, PROTEIN2 aPROTEIN1300 form a ternary complex",HPRD50.d19.s2,p300,MEF2A
129,HPRD50.d19,True,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and PROTEIN1, and our in vivo studies demonstrated that TR, PROTEIN1 aPROTEIN2300 form a ternary complex",HPRD50.d19.s2,MEF2A,p300
130,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and PROTEIN2, and our in vivo studies demonstrated that TR, PROTEIN2 aPROTEIN1300 form a ternary complex",HPRD50.d19.s2,p300,MEF2A
131,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of PROTEIN2EIN1 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and PROTEIN2EIN1 form a ternary complex",HPRD50.d19.s2,p300,p300
132,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and PROTEIN2IN1, and our in vivo studies demonstrated that TR, PROTEIN2IN1 and p300 form a ternary complex",HPRD50.d19.s2,MEF2A,MEF2A
133,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and PROTEIN1, and our in vivo studies demonstrated that TR, PROTEIN1 aPROTEIN2300 form a ternary complex",HPRD50.d19.s2,MEF2A,p300
134,HPRD50.d20,True,"The human PROTEIN1 and PROTEIN2 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0,Imp3,Imp4
135,HPRD50.d20,True,"The human PROTEIN1 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 PROTEIN2 in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0,Imp3,snoRNA
136,HPRD50.d20,True,"The human Imp3 and PROTEIN1 proteins form a ternary complex with hMpp10, which only interacts with the U3 PROTEIN2 in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0,Imp4,snoRNA
137,HPRD50.d20,False,We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins PROTEIN1 and PROTEIN2,HPRD50.d20.s1,Imp3,Imp4
138,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse PROTEIN1, mouse PROTEIN2 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of PROTEIN2 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2,Imp4,Imp3
139,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse PROTEIN1, mouse PROTEIN2 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of PROTEIN2 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2,Imp4,Imp3
140,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse Imp4, mouse PROTEIN2EIN1 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of PROTEIN2EIN1 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2,Imp3,Imp3
141,HPRD50.d20,True,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human PROTEIN1 and Imp4 proteins predominantly interact with the U3 PROTEIN2 in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3,Imp3,snoRNA
142,HPRD50.d20,True,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and PROTEIN1 proteins predominantly interact with the U3 PROTEIN2 in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3,Imp4,snoRNA
143,HPRD50.d20,False,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human PROTEIN1 and PROTEIN2 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3,Imp3,Imp4
144,HPRD50.d21,True,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor PROTEIN1 and the PROTEIN2 (OX1R) using a heterologous system",HPRD50.d21.s0,CB1,orexin 1 receptor
145,HPRD50.d21,True,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor PROTEIN1 and the orexin 1 receptor (PROTEIN2) using a heterologous system",HPRD50.d21.s0,CB1,OX1R
146,HPRD50.d21,False,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the PROTEIN1 (PROTEIN2) using a heterologous system",HPRD50.d21.s0,orexin 1 receptor,OX1R
147,HPRD50.d21,False,"In contrast to PROTEIN1, the potency of direct activation of PROTEIN2 was not affected by co-expression with PROTEIN1",HPRD50.d21.s1,OX1R,CB1
148,HPRD50.d21,False,"In contrast to PROTEIN2EIN1, the potency of direct activation of CB1 was not affected by co-expression with PROTEIN2EIN1",HPRD50.d21.s1,OX1R,OX1R
149,HPRD50.d21,False,"In contrast to PROTEIN2, the potency of direct activation of PROTEIN1 was not affected by co-expression with PROTEIN2",HPRD50.d21.s1,CB1,OX1R
150,HPRD50.d21,False,"In addition, electron microscopy experiments revealed that PROTEIN1 and PROTEIN2 are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers",HPRD50.d21.s2,CB1,OX1R
151,HPRD50.d22,True,"PROTEIN1, a Rho family GTPase-activating protein that interacts with signaling adapters PROTEIN2 and Gab2",HPRD50.d22.s0,GC-GAP,Gab1
152,HPRD50.d22,True,"PROTEIN1, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and PROTEIN2",HPRD50.d22.s0,GC-GAP,Gab2
153,HPRD50.d22,True,"GC-GAP, a Rho family PROTEIN1 that interacts with signaling adapters PROTEIN2 and Gab2",HPRD50.d22.s0,GTPase-activating protein,Gab1
154,HPRD50.d22,True,"GC-GAP, a Rho family PROTEIN1 that interacts with signaling adapters Gab1 and PROTEIN2",HPRD50.d22.s0,GTPase-activating protein,Gab2
155,HPRD50.d22,False,"PROTEIN1, a Rho family PROTEIN2 that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0,GC-GAP,GTPase-activating protein
156,HPRD50.d22,False,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters PROTEIN1 and PROTEIN2",HPRD50.d22.s0,Gab1,Gab2
157,HPRD50.d22,True,"PROTEIN1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as PROTEIN2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab1,Grb2
158,HPRD50.d22,True,"PROTEIN1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, PROTEIN2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab1,Shp-2
159,HPRD50.d22,True,"PROTEIN1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, PROTEIN2, Shc, and Crk",HPRD50.d22.s1,Gab1,phosphatidylinositol 3-kinase
160,HPRD50.d22,True,"Gab1 and PROTEIN1 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as PROTEIN2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab2,Grb2
161,HPRD50.d22,True,"Gab1 and PROTEIN1 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, PROTEIN2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab2,Shp-2
162,HPRD50.d22,True,"Gab1 and PROTEIN1 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, PROTEIN2, Shc, and Crk",HPRD50.d22.s1,Gab2,phosphatidylinositol 3-kinase
163,HPRD50.d22,False,"PROTEIN1 and PROTEIN2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab1,Gab2
164,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as PROTEIN1, PROTEIN2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Grb2,Shp-2
165,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as PROTEIN1, Shp-2, PROTEIN2, Shc, and Crk",HPRD50.d22.s1,Grb2,phosphatidylinositol 3-kinase
166,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, PROTEIN1, PROTEIN2, Shc, and Crk",HPRD50.d22.s1,Shp-2,phosphatidylinositol 3-kinase
167,HPRD50.d22,True,"In addition, PROTEIN1 contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length PROTEIN2 in vitro",HPRD50.d22.s2,GC-GAP,Nck
168,HPRD50.d22,True,"We propose that PROTEIN1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of PROTEIN2 under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,Gab1,GC-GAP
169,HPRD50.d22,True,"We propose that PROTEIN1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and PROTEIN2 activities",HPRD50.d22.s3,Gab1,Cdc42
170,HPRD50.d22,True,"We propose that Gab1 and PROTEIN1 in cooperation with other adapter molecules might regulate the cellular localization of PROTEIN2 under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,Gab2,GC-GAP
171,HPRD50.d22,True,"We propose that Gab1 and PROTEIN1 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and PROTEIN2 activities",HPRD50.d22.s3,Gab2,Cdc42
172,HPRD50.d22,False,"We propose that PROTEIN1 and PROTEIN2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,Gab1,Gab2
173,HPRD50.d22,False,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of PROTEIN1 under specific stimuli, acting to regulate precisely Rac and PROTEIN2 activities",HPRD50.d22.s3,GC-GAP,Cdc42
174,HPRD50.d22,False,This work led to identification of a novel PROTEIN1 (PROTEIN2) for Rho family GTPases,HPRD50.d22.s4,GTPase-activating protein,GAP
175,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned PROTEIN1 and displays activity toward RhoA, PROTEIN2, and Cdc42 in vitro",HPRD50.d22.s5,CdGAP,Rac1
176,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned PROTEIN1 and displays activity toward RhoA, Rac1, and PROTEIN2 in vitro",HPRD50.d22.s5,CdGAP,Cdc42
177,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, PROTEIN1, and PROTEIN2 in vitro",HPRD50.d22.s5,Rac1,Cdc42
178,HPRD50.d22,True,The protein was named PROTEIN1 for its ability to interact with PROTEIN2 proteins and its activity toward Rac and Cdc42,HPRD50.d22.s6,GC-GAP,GAB
179,HPRD50.d22,True,The protein was named PROTEIN1 for its ability to interact with GAB proteins and its activity toward Rac and PROTEIN2,HPRD50.d22.s6,GC-GAP,Cdc42
180,HPRD50.d22,False,The protein was named GC-GAP for its ability to interact with PROTEIN1 proteins and its activity toward Rac and PROTEIN2,HPRD50.d22.s6,GAB,Cdc42
181,HPRD50.d22,True,Expression of PROTEIN1 in 293T cells led to a reduction in active PROTEIN2 and Cdc42 levels but not RhoA,HPRD50.d22.s7,GC-GAP,Rac1
182,HPRD50.d22,True,Expression of PROTEIN1 in 293T cells led to a reduction in active Rac1 and PROTEIN2 levels but not RhoA,HPRD50.d22.s7,GC-GAP,Cdc42
183,HPRD50.d22,False,Expression of GC-GAP in 293T cells led to a reduction in active PROTEIN1 and PROTEIN2 levels but not RhoA,HPRD50.d22.s7,Rac1,Cdc42
184,HPRD50.d23,True,A role for PROTEIN1 phosphorylation of PROTEIN2 in cytokinesis,HPRD50.d23.s0,Plk1,NudC
185,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and PROTEIN2, show that Plk1 phosphorylates PROTEIN2 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN2 is also a substrPROTEIN1for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
186,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and PROTEIN2, show that Plk1 phosphorylates PROTEIN2 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN2 is also a substrPROTEIN1for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
187,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and PROTEIN1, show that Plk1 phosphorylates PROTEIN1 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN1 is also a substrPROTEIN2for Plk1 in vivo",HPRD50.d23.s1,NudC,Plk1
188,HPRD50.d23,False,"Here, we characterize the interaction between PROTEIN1 and NudC, show that PROTEIN1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate PROTEIN2PROTEIN1 in vivo",HPRD50.d23.s1,Plk1,Plk1
189,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN2, show that Plk1 phosphorylates PROTEIN2 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN2 is also a substrPROTEIN1for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
190,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN2, show that Plk1 phosphorylates PROTEIN2 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN2 is also a substrPROTEIN1for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
191,HPRD50.d23,False,"Here, we characterize the interaction between PROTEIN1 and NudC, show that PROTEIN1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate PROTEIN2PROTEIN1 in vivo",HPRD50.d23.s1,Plk1,Plk1
192,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN1, show that Plk1 phosphorylates PROTEIN1 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN1 is also a substrPROTEIN2for Plk1 in vivo",HPRD50.d23.s1,NudC,Plk1
193,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN1, show tPROTEIN2Plk1 phosphorylates PROTEIN1 at conserved S274 and S326 residues in vitro, and present evidence tPROTEIN2PROTEIN1 is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,NudC
194,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN1, show tPROTEIN2Plk1 phosphorylates PROTEIN1 at conserved S274 and S326 residues in vitro, and present evidence tPROTEIN2PROTEIN1 is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,NudC
195,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN1, show that Plk1 phosphorylates PROTEIN1 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN1 is also a substrPROTEIN2for Plk1 in vivo",HPRD50.d23.s1,NudC,Plk1
196,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN2, show that Plk1 phosphorylates PROTEIN2 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN2 is also a substrPROTEIN1for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
197,HPRD50.d23,False,"Here, we characterize the interaction between PROTEIN1 and NudC, show that PROTEIN1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate PROTEIN2PROTEIN1 in vivo",HPRD50.d23.s1,Plk1,Plk1
198,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN1, show tPROTEIN2Plk1 phosphorylates PROTEIN1 at conserved S274 and S326 residues in vitro, and present evidence tPROTEIN2PROTEIN1 is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,NudC
199,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and PROTEIN1, show that Plk1 phosphorylates PROTEIN1 at conserved S274 and S326 residues in vitro, and present evidence that PROTEIN1 is also a substrPROTEIN2for Plk1 in vivo",HPRD50.d23.s1,NudC,Plk1
200,HPRD50.d23,False,"Downregulation of PROTEIN1PROTEIN2RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescuedPROTEIN2ectopic expression of wild-type PROTEIN1, but notPROTEIN2PROTEIN1 with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,NudC
201,HPRD50.d23,False,"Downregulation of PROTEIN1PROTEIN2RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescuedPROTEIN2ectopic expression of wild-type PROTEIN1, but notPROTEIN2PROTEIN1 with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,NudC
202,HPRD50.d23,False,"Downregulation of PROTEIN1 by RNA interference resultsPROTEIN2multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type PROTEIN1, but not by PROTEIN1 with mutationsPROTEIN2the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,Plk1
203,HPRD50.d23,False,"Downregulation of PROTEIN1PROTEIN2RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescuedPROTEIN2ectopic expression of wild-type PROTEIN1, but notPROTEIN2PROTEIN1 with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,NudC
204,HPRD50.d23,False,"Downregulation of PROTEIN1 by RNA interference resultsPROTEIN2multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type PROTEIN1, but not by PROTEIN1 with mutationsPROTEIN2the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,Plk1
205,HPRD50.d23,False,"Downregulation of PROTEIN1 by RNA interference resultsPROTEIN2multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type PROTEIN1, but not by PROTEIN1 with mutationsPROTEIN2the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,Plk1
206,HPRD50.d23,True,These results suggest that PROTEIN1 phosphorylation of PROTEIN2 may influence cytokinesis,HPRD50.d23.s3,Plk1,NudC
207,HPRD50.d24,True,Specific interaction of PROTEIN1 and c/EBPbeta leads to the transcriptional activation of the human PROTEIN2 gene,HPRD50.d24.s0,Egr1,low density lipoprotein receptor
208,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the PROTEIN1 (LDLR) promoter mediates PROTEIN2 (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDL receptor,oncostatin M
209,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the LDL receptor (PROTEIN1) promoter mediates PROTEIN2 (OM)-induced transcription of the PROTEIN1 gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDLR,oncostatin M
210,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the LDL receptor (PROTEIN2) promoter mediates PROTEIN1 (OM)-induced transcription of the PROTEIN2 gene through a cholesterol-independent pathway,HPRD50.d24.s1,oncostatin M,LDLR
211,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the PROTEIN1 (PROTEIN2) promoter mediates oncostatin M (OM)-induced transcription of the PROTEIN2 gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDL receptor,LDLR
212,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the PROTEIN1 (PROTEIN2) promoter mediates oncostatin M (OM)-induced transcription of the PROTEIN2 gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDL receptor,LDLR
213,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the LDL receptor (PROTEIN2EIN1) promoter mediates oncostatin M (OM)-induced transcription of the PROTEIN2EIN1 gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDLR,LDLR
214,HPRD50.d25,True,PROTEIN1 orphan receptor functions as negative modulator for PROTEIN2 in prostate cancer cells PC-3,HPRD50.d25.s0,TR2,androgen receptor
215,HPRD50.d25,False,PROTEIN1 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PROTEIN2,HPRD50.d25.s0,TR2,PC-3
216,HPRD50.d25,False,TR2 orphan receptor functions as negative modulator for PROTEIN1 in prostate cancer cells PROTEIN2,HPRD50.d25.s0,androgen receptor,PC-3
217,HPRD50.d25,False,BACKGROUND: Both PROTEIN1 (AR) and orphan receptor PROTEIN2 (PROTEIN2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1,androgen receptor,TR2
218,HPRD50.d25,False,BACKGROUND: Both PROTEIN1 (AR) and orphan receptor PROTEIN2 (PROTEIN2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1,androgen receptor,TR2
219,HPRD50.d25,False,BACKGROUND: Both androgen receptor (AR) and orphan receptor PROTEIN2TEIN1 (PROTEIN2TEIN1) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1,TR2,TR2
220,HPRD50.d25,False,The interaction between AR and PROTEIN1 was assessed by PROTEIN2 (GST) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2,TR2,glutathione-S-transferase
221,HPRD50.d25,False,The interaction between AR and PROTEIN1 was assessed by glutathione-S-transferase (PROTEIN2) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2,TR2,GST
222,HPRD50.d25,False,The interaction between AR and TR2 was assessed by PROTEIN1 (PROTEIN2) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2,glutathione-S-transferase,GST
223,HPRD50.d26,True,The protein PROTEIN1 functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor PROTEIN2 for proteasomal degradation during normoxia,HPRD50.d26.s0,pVHL,Hif1 alpha
224,HPRD50.d26,True,"We establish that PROTEIN1 binds to PROTEIN2 (TBP-1), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1,pVHL,Tat-binding protein-1
225,HPRD50.d26,True,"We establish that PROTEIN1 binds to Tat-binding protein-1 (PROTEIN2), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1,pVHL,TBP-1
226,HPRD50.d26,False,"We establish that pVHL binds to PROTEIN1 (PROTEIN2), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1,Tat-binding protein-1,TBP-1
227,HPRD50.d26,True,PROTEIN1 associates with the beta-domain of PROTEIN2 and complexes with PROTEIN2 and Hif1 alpha in vivo,HPRD50.d26.s2,TBP-1,pVHL
228,HPRD50.d26,True,PROTEIN1 associates with the beta-domain of PROTEIN2 and complexes with PROTEIN2 and Hif1 alpha in vivo,HPRD50.d26.s2,TBP-1,pVHL
229,HPRD50.d26,True,PROTEIN1 associates with the beta-domain of pVHL and complexes with pVHL and PROTEIN2 in vivo,HPRD50.d26.s2,TBP-1,Hif1 alpha
230,HPRD50.d26,False,TBP-1 associates with the beta-domain of PROTEIN2EIN1 and complexes with PROTEIN2EIN1 and Hif1 alpha in vivo,HPRD50.d26.s2,pVHL,pVHL
231,HPRD50.d26,False,TBP-1 associates with the beta-domain of PROTEIN1 and complexes with PROTEIN1 PROTEIN2lpha in vivo,HPRD50.d26.s2,pVHL,Hif1 alpha
232,HPRD50.d26,False,TBP-1 associates with the beta-domain of PROTEIN1 and complexes with PROTEIN1 PROTEIN2lpha in vivo,HPRD50.d26.s2,pVHL,Hif1 alpha
233,HPRD50.d26,True,Overexpression of PROTEIN1 promotes degradation of PROTEIN2 in a pVHL-dependent manner that requires the ATPase domain of PROTEIN1,HPRD50.d26.s3,TBP-1,Hif1 alpha
234,HPRD50.d26,True,Overexpression of PROTEIN2 promotes degradation of PROTEIN1 in a pVHL-dependent manner that requires the ATPase domain of PROTEIN2,HPRD50.d26.s3,Hif1 alpha,TBP-1
235,HPRD50.d26,False,Overexpression of PROTEIN2IN1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of PROTEIN2IN1,HPRD50.d26.s3,TBP-1,TBP-1
236,HPRD50.d26,True,Blockade of PROTEIN1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of PROTEIN2,HPRD50.d26.s4,TBP-1,Hif1 alpha
237,HPRD50.d26,True,Several distinct mutations in exon 2 of PROTEIN1 disrupt binding of pPROTEINPROTEIN2TBP-1,HPRD50.d26.s5,VHL,TBP-1
238,HPRD50.d26,True,Several distinct mutations in exon 2 of VHL disrupt binding of PROTEIN1 to PROTEIN2,HPRD50.d26.s5,pVHL,TBP-1
239,HPRD50.d26,False,Several distinct mutations in exon 2 of PROTEIN1 disrupt binding of PROTEIN2TEIN1 to TBP-1,HPRD50.d26.s5,VHL,pVHL
240,HPRD50.d26,True,"A PROTEIN1 mutant containing a P154L substitution coimmunoprecipitates with PROTEIN2, but not TBP-1, and does not promote degradation of PROTEIN2",HPRD50.d26.s6,pVHL,Hif1 alpha
241,HPRD50.d26,False,"A PROTEIN1 mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not PROTEIN2, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6,pVHL,TBP-1
242,HPRD50.d26,False,"A PROTEIN1 mutant containing a P154L substitution coimmunoprecipitates with PROTEIN2, but not TBP-1, and does not promote degradation of PROTEIN2",HPRD50.d26.s6,pVHL,Hif1 alpha
243,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with PROTEIN1, but not PROTEIN2, and does not promote degradation of PROTEIN1",HPRD50.d26.s6,Hif1 alpha,TBP-1
244,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with PROTEIN2, but not TBP-1, and does not promote degradation of PROTEIN2",HPRD50.d26.s6,Hif1 alpha,Hif1 alpha
245,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with PROTEIN2, but not PROTEIN1, and does not promote degradation of PROTEIN2",HPRD50.d26.s6,TBP-1,Hif1 alpha
246,HPRD50.d26,True,"Thus, the ability of pVHL to degrade PROTEIN2 depends in part on its interaction with TBP-1 and suggests a new mechanism for PROTEIN2 stabilization in some pVPROTEIN1eficient tumors",HPRD50.d26.s7,pVHL,Hif1 alpha
247,HPRD50.d26,True,"Thus, the ability of PROTEIN1 to degrade Hif1 alpha depends in part on its interaction with PROTEIN2 and suggests a new mechanism for Hif1 alpha stabilization in some PROTEIN1-deficient tumors",HPRD50.d26.s7,pVHL,TBP-1
248,HPRD50.d26,True,"Thus, the ability of pVHL to degrade PROTEIN1 depends in part on its interaction with TBP-1 and suggests a new mechanism for PROTEIN1 stabilization in some pVPROTEIN2eficient tumors",HPRD50.d26.s7,Hif1 alpha,pVHL
249,HPRD50.d26,False,"Thus, the ability of pVHL to degrade PROTEIN2 depends in part on its interaction with TBP-1 and suggests a new mechanism for PROTEIN2 stabilization in some pVPROTEIN1eficient tumors",HPRD50.d26.s7,pVHL,Hif1 alpha
250,HPRD50.d26,False,"Thus, the ability of PROTEIN2EIN1 to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some PROTEIN2EIN1-deficient tumors",HPRD50.d26.s7,pVHL,pVHL
251,HPRD50.d26,False,"Thus, the ability of pVHL to degrade PROTEIN1 depends in part on its interaction with PROTEIN2 and suggests a new mechanism for PROTEIN1 stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,Hif1 alpha,TBP-1
252,HPRD50.d26,False,"Thus, the ability of pVHL to degrade PROTEIN1 depends in part on its interaction with TBP-1 and suggests a new mechanism for PROTEIN2tabilization in some pVHL-deficient tumors",HPRD50.d26.s7,Hif1 alpha,Hif1 alpha
253,HPRD50.d26,False,"Thus, the ability of pVHL to degrade PROTEIN1 depends in part on its interaction with TBP-1 and suggests a new mechanism for PROTEIN1 stabilization in some pVPROTEIN2eficient tumors",HPRD50.d26.s7,Hif1 alpha,pVHL
254,HPRD50.d26,False,"Thus, the ability of pVHL to degrade PROTEIN2 depends in part on its interaction with PROTEIN1 and suggests a new mechanism for PROTEIN2 stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,TBP-1,Hif1 alpha
255,HPRD50.d26,False,"Thus, the ability of PROTEIN2 to degrade Hif1 alpha depends in part on its interaction with PROTEIN1 and suggests a new mechanism for Hif1 alpha stabilization in some PROTEIN2-deficient tumors",HPRD50.d26.s7,TBP-1,pVHL
256,HPRD50.d27,True,"PROTEIN1/DRS/memA interacts with PROTEIN2, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,Pinin,SRp75
257,HPRD50.d27,True,"PROTEIN1/DRS/memA interacts with SRp75, PROTEIN2 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,Pinin,SRm300
258,HPRD50.d27,True,"Pinin/PROTEIN1/memA interacts with PROTEIN2, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,DRS,SRp75
259,HPRD50.d27,True,"Pinin/PROTEIN1/memA interacts with SRp75, PROTEIN2 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,DRS,SRm300
260,HPRD50.d27,False,"PROTEIN1/PROTEIN2/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,Pinin,DRS
261,HPRD50.d27,False,"Pinin/DRS/memA interacts with PROTEIN1, PROTEIN2 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,SRp75,SRm300
262,HPRD50.d27,False,"Three SR-rich proteins were identified that interact with the C-terminus of Pnn: PROTEIN1 and PROTEIN2, known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130",HPRD50.d27.s1,SRp75,SRm300
263,HPRD50.d29,True,Modification of de novo DNA methyltransferase 3a (PROTEIN1) by PROTEIN2 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription,HPRD50.d29.s0,Dnmt3a,SUMO-1
264,HPRD50.d29,True,"Here we show that PROTEIN1 interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme PROTEIN2 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Dnmt3a,Ubc9
265,HPRD50.d29,True,"Here we show that PROTEIN1 interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PROTEIN2 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Dnmt3a,PIAS1
266,HPRD50.d29,True,"Here we show that PROTEIN1 interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PROTEIN2, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Dnmt3a,PIASxalpha
267,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme PROTEIN1 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, PROTEIN2, to its target proteins",HPRD50.d29.s1,Ubc9,SUMO-1
268,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PROTEIN1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, PROTEIN2, to its target proteins",HPRD50.d29.s1,PIAS1,SUMO-1
269,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PROTEIN1, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, PROTEIN2, to its target proteins",HPRD50.d29.s1,PIASxalpha,SUMO-1
270,HPRD50.d29,False,"Here we show that PROTEIN1 interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, PROTEIN2, to its target proteins",HPRD50.d29.s1,Dnmt3a,SUMO-1
271,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme PROTEIN1 and the E3 sumo ligases PROTEIN2 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Ubc9,PIAS1
272,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme PROTEIN1 and the E3 sumo ligases PIAS1 and PROTEIN2, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Ubc9,PIASxalpha
273,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PROTEIN1 and PROTEIN2, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,PIAS1,PIASxalpha
274,HPRD50.d29,True,PROTEIN1 is modified by PROTEIN2 in vivo and in vitro and the region of PROTEIN1 responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2,Dnmt3a,SUMO-1
275,HPRD50.d29,False,PROTEIN2N1 is modified by SUMO-1 in vivo and in vitro and the region of PROTEIN2N1 responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2,Dnmt3a,Dnmt3a
276,HPRD50.d29,False,PROTEIN2 is modified by PROTEIN1 in vivo and in vitro and the region of PROTEIN2 responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2,SUMO-1,Dnmt3a
277,HPRD50.d29,True,"Functionally, sumoylation of PROTEIN1 disrupts its ability to interact with histone deacetylases (PROTEIN2/2), but not with another interaction partner, Dnmt3b",HPRD50.d29.s3,Dnmt3a,HDAC1
278,HPRD50.d29,False,"Functionally, sumoylation of PROTEIN1 disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, PROTEIN2",HPRD50.d29.s3,Dnmt3a,Dnmt3b
279,HPRD50.d29,False,"Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (PROTEIN1/2), but not with another interaction partner, PROTEIN2",HPRD50.d29.s3,HDAC1,Dnmt3b
280,HPRD50.d30,True,The tyrosine kinase PROTEIN1 is physically associated with the Type I interferon (PROTEIN2) receptor complex and is rapidly activated during PROTEIN2 alpha stimulation,HPRD50.d30.s0,Tyk-2,IFN
281,HPRD50.d30,True,The tyrosine kinase PROTEIN1 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during PROTEIN2 stimulation,HPRD50.d30.s0,Tyk-2,IFN alpha
282,HPRD50.d30,False,The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (PROTEIN1) receptor complex and is rapidly activated during PROTEIN2alpha stimulation,HPRD50.d30.s0,IFN,IFN alpha
283,HPRD50.d31,True,PROTEIN1 interaction with PROTEIN2 phosphatase ties mitogenic signal transduction to cell cycle activation,HPRD50.d31.s0,Raf1,Cdc25
284,HPRD50.d31,True,We show here that PROTEIN1 phosphatase associates with PROTEIN2 in somatic mammalian cells and in meiotic frog oocytes,HPRD50.d31.s1,Cdc25,raf1
285,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (PROTEIN1, PROTEIN2, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,perlecan,biglycan
286,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (PROTEIN1, biglycan, PROTEIN2, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,perlecan,decorin
287,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (PROTEIN1, biglycan, decorin, and PROTEIN2) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,perlecan,versican
288,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, PROTEIN1, PROTEIN2, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,biglycan,decorin
289,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, PROTEIN1, decorin, and PROTEIN2) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,biglycan,versican
290,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, PROTEIN1, and PROTEIN2) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,decorin,versican
291,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of PROTEIN1, a specific heparan sulfate proteoglycan, to the PROTEIN2 protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,perlecan,beta-amyloid
292,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of PROTEIN1, a specific heparan sulfate proteoglycan, to the beta-PROTEIN2 protein (A beta)-containing PROTEIN2 deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,perlecan,amyloid
293,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific PROTEIN1, to the PROTEIN2 protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,heparan sulfate proteoglycan,beta-amyloid
294,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific PROTEIN1, to the beta-PROTEIN2 protein (A beta)-containing PROTEIN2 deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,heparan sulfate proteoglycan,amyloid
295,HPRD50.d32,False,"Previous studies have demonstrated the immunolocalization of PROTEIN1, a specific PROTEIN2, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,perlecan,heparan sulfate proteoglycan
296,HPRD50.d32,False,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the PROTEIN1 protein (A beta)-containing PROTEIN2 deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,beta-amyloid,amyloid
297,HPRD50.d32,False,"Overall, the results indicate that specific vascular cell-derived PROTEIN1 differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of PROTEIN2",HPRD50.d32.s2,PGs,perlecan
298,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (PROTEIN1)-derived PROTEIN2 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3,SMC,PGs
299,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (PROTEIN1)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular PROTEIN2 deposits may be due to its interactions with perlecan",HPRD50.d32.s3,SMC,amyloid
300,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (PROTEIN1)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with PROTEIN2",HPRD50.d32.s3,SMC,perlecan
301,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PROTEIN1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular PROTEIN2 deposits may be due to its interactions with perlecan",HPRD50.d32.s3,PGs,amyloid
302,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PROTEIN1 to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with PROTEIN2",HPRD50.d32.s3,PGs,perlecan
303,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular PROTEIN1 deposits may be due to its interactions with PROTEIN2",HPRD50.d32.s3,amyloid,perlecan
304,HPRD50.d32,False,"Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in PROTEIN1 which was partially removed by pretreatment with heparitinase, but not by chondroitin PROTEIN2 lyase",HPRD50.d32.s4,perlecan,ABC
305,HPRD50.d32,False,"[35S]-Sulfate labeled proteoglycans (PROTEIN1) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine PROTEIN2",HPRD50.d32.s5,PGs,serum albumin
306,HPRD50.d32,True,"Characterization of EC and SMC PROTEIN1 bound to A beta (1-28) revealed strong binding by PROTEIN2, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,perlecan
307,HPRD50.d32,True,"Characterization of EC and SMC PROTEIN1 bound to A beta (1-28) revealed strong binding by perlecan, weak binding by PROTEIN2 and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,decorin
308,HPRD50.d32,True,"Characterization of EC and SMC PROTEIN1 bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and PROTEIN2, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,biglycan
309,HPRD50.d32,False,"Characterization of EC and PROTEIN1 PROTEIN2 bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,PGs
310,HPRD50.d32,False,"Characterization of EC and PROTEIN1 PGs bound to A beta (1-28) revealed strong binding by PROTEIN2, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,perlecan
311,HPRD50.d32,False,"Characterization of EC and PROTEIN1 PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by PROTEIN2 and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,decorin
312,HPRD50.d32,False,"Characterization of EC and PROTEIN1 PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and PROTEIN2, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,biglycan
313,HPRD50.d32,False,"Characterization of EC and PROTEIN1 PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by PROTEIN2/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,versican
314,HPRD50.d32,False,"Characterization of EC and PROTEIN1 PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PROTEIN2, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,PG-M
315,HPRD50.d32,False,"Characterization of EC and SMC PROTEIN1 bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by PROTEIN2/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,versican
316,HPRD50.d32,False,"Characterization of EC and SMC PROTEIN1 bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PROTEIN2, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,PG-M
317,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by PROTEIN1, weak binding by PROTEIN2 and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,perlecan,decorin
318,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by PROTEIN1, weak binding by decorin and PROTEIN2, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,perlecan,biglycan
319,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by PROTEIN1, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by PROTEIN2/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,perlecan,versican
320,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by PROTEIN1, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PROTEIN2, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,perlecan,PG-M
321,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by PROTEIN1 and PROTEIN2, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,decorin,biglycan
322,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by PROTEIN1 and biglycan, two dermatan sulfate proteoglycans, and lack of binding by PROTEIN2/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,decorin,versican
323,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by PROTEIN1 and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PROTEIN2, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,decorin,PG-M
324,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and PROTEIN1, two dermatan sulfate proteoglycans, and lack of binding by PROTEIN2/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,biglycan,versican
325,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and PROTEIN1, two dermatan sulfate proteoglycans, and lack of binding by versican/PROTEIN2, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,biglycan,PG-M
326,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by PROTEIN1/PROTEIN2, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,versican,PG-M
327,HPRD50.d33,True,"Cross-linking of PROTEIN1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag PROTEIN2, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0,CD53,CD69
328,HPRD50.d33,True,"Cross-linking of PROTEIN1 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and PROTEIN2 protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0,CD53,c-myc
329,HPRD50.d33,False,"Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag PROTEIN1, increases in cellular volume, RNA synthesis, and PROTEIN2 protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0,CD69,c-myc
330,HPRD50.d33,True,"However, cytokines, in particular PROTEIN1 and IL-4, potentiated the DNA synthesis induced by cross-linking of PROTEIN2",HPRD50.d33.s1,IL-2,CD53
331,HPRD50.d33,True,"However, cytokines, in particular IL-2 and PROTEIN1, potentiated the DNA synthesis induced by cross-linking of PROTEIN2",HPRD50.d33.s1,IL-4,CD53
332,HPRD50.d33,False,"However, cytokines, in particular PROTEIN1 and PROTEIN2, potentiated the DNA synthesis induced by cross-linking of CD53",HPRD50.d33.s1,IL-2,IL-4
333,HPRD50.d34,False,The human PROTEIN1 mRNA editing protein is a PROTEIN2 showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases,HPRD50.d34.s0,apoB,cytidine deaminase
334,HPRD50.d34,False,The fact that the PROTEIN1 mRNA editing protein also exists as a PROTEIN2 has important implications for the mechanism of PROTEIN1 mRNA editing in humans,HPRD50.d34.s1,apoB,homodimer
335,HPRD50.d34,False,The fact that the PROTEIN2EIN1 mRNA editing protein also exists as a homodimer has important implications for the mechanism of PROTEIN2EIN1 mRNA editing in humans,HPRD50.d34.s1,apoB,apoB
336,HPRD50.d34,False,The fact that the PROTEIN2 mRNA editing protein also exists as a PROTEIN1 has important implications for the mechanism of PROTEIN2 mRNA editing in humans,HPRD50.d34.s1,homodimer,apoB
337,HPRD50.d35,False,"Assignment of PROTEIN1, PROTEIN2, and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human",HPRD50.d35.s0,Etfdh,Etfb
338,HPRD50.d35,False,"We used cDNA probes for the PROTEIN1, PROTEIN2, and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13",HPRD50.d35.s1,Etfdh,Etfb
339,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving PROTEIN1 cross-linked either to itself or to a variety of other known CE protein components, including PROTEIN2, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,involucrin,cystatin alpha
340,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving PROTEIN1 cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, PROTEIN2, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the PROTEIN2 family",HPRD50.d38.s0,involucrin,desmoplakin
341,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving PROTEIN1 cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, PROTEIN2, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,involucrin,elafin
342,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving PROTEIN1 cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, PROTEIN2, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,involucrin,loricrin
343,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving PROTEIN1 cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, PROTEIN2, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the PROTEIN2 family",HPRD50.d38.s0,involucrin,desmoplakin
344,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including PROTEIN1, PROTEIN2, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the PROTEIN2 family",HPRD50.d38.s0,cystatin alpha,desmoplakin
345,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including PROTEIN1, desmoplakin, PROTEIN2, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,cystatin alpha,elafin
346,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including PROTEIN1, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, PROTEIN2, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,cystatin alpha,loricrin
347,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including PROTEIN1, PROTEIN2, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the PROTEIN2 family",HPRD50.d38.s0,cystatin alpha,desmoplakin
348,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, PROTEIN1, PROTEIN2, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the PROTEIN1 family",HPRD50.d38.s0,desmoplakin,elafin
349,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, PROTEIN1, elafin, keratins, members of the small proline-rich superfamily, PROTEIN2, and unknown proteins related to the PROTEIN1 family",HPRD50.d38.s0,desmoplakin,loricrin
350,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, PROTEIN1, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the PROTEIN2mily",HPRD50.d38.s0,desmoplakin,desmoplakin
351,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, PROTEIN1, keratins, members of the small proline-rich superfamily, PROTEIN2, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,elafin,loricrin
352,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, PROTEIN2, PROTEIN1, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the PROTEIN2 family",HPRD50.d38.s0,elafin,desmoplakin
353,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, PROTEIN2, elafin, keratins, members of the small proline-rich superfamily, PROTEIN1, and unknown proteins related to the PROTEIN2 family",HPRD50.d38.s0,loricrin,desmoplakin
354,HPRD50.d38,False,"Specific glutamines or lysines of PROTEIN1 were used to cross-link the different proteins, such as glutamines 495 and 496 to PROTEIN2, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain PROTEIN1 cross-links",HPRD50.d38.s1,involucrin,desmoplakin
355,HPRD50.d38,False,"Specific glutamines or lysines of PROTEIN1 were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain PROTEIN2ross-links",HPRD50.d38.s1,involucrin,involucrin
356,HPRD50.d38,False,"Specific glutamines or lysines of PROTEIN2 were used to cross-link the different proteins, such as glutamines 495 and 496 to PROTEIN1, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain PROTEIN2 cross-links",HPRD50.d38.s1,desmoplakin,involucrin
357,HPRD50.d39,True,"A prominent isolate, designated PROTEIN1/CASP10, specifically interacts with the PROTEIN2 not only in vivo but also in vitro",HPRD50.d39.s0,SRcyp,CTD
358,HPRD50.d39,True,"A prominent isolate, designated SRcyp/PROTEIN1, specifically interacts with the PROTEIN2 not only in vivo but also in vitro",HPRD50.d39.s0,CASP10,CTD
359,HPRD50.d39,False,"A prominent isolate, designated PROTEIN1/PROTEIN2, specifically interacts with the CTD not only in vivo but also in vitro",HPRD50.d39.s0,SRcyp,CASP10
360,HPRD50.d39,False,PROTEIN1 is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing PROTEIN2,HPRD50.d39.s1,SRcyp,splicing factor SC35
361,HPRD50.d40,True,Transient expression of the full-length PROTEIN1 without RSRS in U1240MG glioblastoma cells resulted in repression of PROTEIN2 promoter activity,HPRD50.d40.s0,E2-2,FGF-1.B
362,HPRD50.d40,True,These results suggest that the relative abundance of the two splice variants of PROTEIN1 in brain could be an important determinant for the expression of PROTEIN2,HPRD50.d40.s1,E2-2,FGF-1
